Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.
Journal: Cancer research
Published: December 31, 2021
Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-Guided First-in-Human Studies.
Journal: Clinical and translational science
Published: May 21, 2020
Synthetic lethality as an engine for cancer drug target discovery.
Journal: Nature reviews. Drug discovery
Published: September 12, 2019
Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
Journal: Nature communications
Published: January 16, 2019
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
Journal: Nature communications
Published: October 08, 2017
Showing 1-6 of 6
Last Updated: 09/26/2026